Jci_page_head_homepage_01 Jci_page_head_homepage_02
Ekihiro Seki, Samuele De Minicis, Geum-Youn Gwak, Johannes Kluwe, Sayaka Inokuchi, Christina A. Bursill, Josep M. Llovet, David A. Brenner, Robert F. Schwabe
Published in Volume 119, Issue 7
J Clin Invest. 2009; 119(7):1858–1870 doi:10.1172/JCI37444
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Jci37444
Figure 8
CCR1-deficient BM reduces fibrosis in CCR5-deficient mice.

BMT was performed to generate wild-type mice with wild-type BM, Ccr5–/– mice with Ccr5–/– BM, and Ccr5–/– mice with Ccr1–/– BM. Three months after BMT, mice underwent BDL for 3 weeks or received 12 injections of CCl4. (A) Successful BMT was tested by comparing splenic levels of Ccr1 and Ccr5 mRNA. (BG) Hepatic fibrosis was evaluated by Sirius red staining (B and E; original magnification, ×100), quantification of the Sirius red–positive area (C and F), and quantification of hepatic hydroxyproline (D and G).*P < 0.05, **P < 0.01.